Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 1 · 25%High 2 · 50%

Overall Survival** · locally advanced or metastatic breast cancer

PARPi‐containing regimen showed no clear difference in overall Survival** compared with non‐PARPi regimen (high certainty).

1 finding from 1 review

Progression‐free survival · locally advanced or metastatic breast cancer

PARPi‐containing regimen leads to lower progression Free Survival** compared with non‐PARPi regimen (high certainty).

1 finding from 1 review

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer 2021 · Cochrane Headline outcomes only
HR 0.63 [0.56, 0.71]
5 studies · 1474 participants
High

Response rate · locally advanced or metastatic breast cancer

PARPi‐containing regimen may leads to higher response Rate compared with non‐PARPi regimen (low certainty).

1 finding from 1 review

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer 2021 · Cochrane Headline outcomes only
RR 1.39 [1.24, 1.54]
5 studies · 1185 participants
Low

Grade ≥3 AEs · locally advanced or metastatic breast cancer

PARPi‐containing regimen showed no clear difference in grade ≥3 AEs compared with non‐PARPi regimen (moderate certainty).

1 finding from 1 review

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer 2021 · Cochrane Headline outcomes only
RR 0.98 [0.91, 1.04]
5 studies · 1443 participants
Moderate